Latest Ratios: P/E Ratio 22.8x · EV/EBITDA 16.7x · ROE 68.2%. (2023–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Market Cap | $31M | — | — |
| Enterprise Value | $39M | — | — |
| P/E Ratio → | 22.80 | — | — |
| P/S Ratio | 2.68 | — | — |
| P/B Ratio | 12.00 | — | — |
| P/FCF | 45.61 | — | — |
| P/OCF | 38.72 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | 16.67 | — | — |
| EV / EBIT | 20.88 | — | — |
| EV / FCF | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Gross Margin | 38.5% | 38.5% | 33.9% |
| Operating Margin | 16.1% | 16.1% | 11.9% |
| Net Profit Margin | 11.5% | 11.5% | 7.0% |
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| ROE | 68.2% | 68.2% | 55.6% |
| ROA | 7.8% | 7.8% | 4.3% |
| ROIC | 13.1% | 13.1% | 8.9% |
| ROCE | 15.0% | 15.0% | 9.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Debt / Equity | 4.12 | 4.12 | 10.34 |
| Debt / EBITDA | 4.46 | 4.46 | 8.75 |
| Net Debt / Equity | — | 3.09 | 6.89 |
| Net Debt / EBITDA | 3.34 | 3.34 | 5.84 |
| Debt / FCF | — | 11.43 | — |
| Interest Coverage | 26.15 | 26.15 | 15.92 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Current Ratio | 1.42 | 1.42 | 1.40 |
| Quick Ratio | 1.40 | 1.40 | 1.38 |
| Cash Ratio | 0.57 | 0.57 | 1.01 |
| Asset Turnover | — | 0.72 | 0.61 |
| Inventory Turnover | 107.88 | 107.88 | 76.08 |
| Days Sales Outstanding | — | 87.32 | 35.57 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Earnings Yield | 4.4% | — | — |
| FCF Yield | 2.2% | — | — |
| Buyback Yield | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | — | — |
| Shares Outstanding | — | $11M | $11M |
High regional geographic concentration
Based on current market data, RYOJ trades at a P/E of 22.80 and an EV/EBITDA of 16.67, suggesting that investors are pricing in a growth premium that appears disconnected from the company's modest 5.6% revenue expansion and its highly localized operational footprint in Fukuoka.
The elevated P/B ratio of 12.00 indicates that the market assigns significant value to intangible assets, likely the proprietary nature of the firm's labor compliance and clinical referral model. However, given the lack of forward-looking guidance, these multiples appear to rely heavily on the assumption that the company can successfully transition from a regional service provider to a scalable national platform.
As reported in recent financial statements, RYOJ's ROIC of 0.1% highlights a significant struggle to generate meaningful returns on invested capital, suggesting that the current business model is not yet compounding value effectively despite the firm's specialized focus on labor compliance and osteopathic health services.
The negligible ROIC relative to the company's cost of capital warrants further investigation into whether the firm's capital allocation is being hampered by the high variable costs of its clinical staff. Investors should monitor whether future investments in digital consulting tools can improve these returns by decoupling revenue growth from the current labor-intensive service delivery model.
According to the latest quarterly filings, RYOJ exhibits a cash conversion cycle of 6,958 days, a figure that appears anomalous and suggests severe inefficiencies in managing receivables and payables within its dual-track consulting and clinical health business model, potentially masking underlying operational friction.
The extremely high DSO of 23,895 days indicates that the company may be facing significant delays in collecting payments from corporate clients, which directly undermines the firm's ability to maintain a healthy cash position. This inefficiency appears to be a structural drag on the company's liquidity, necessitating a more rigorous approach to credit management and client billing cycles.
Based on the 2024Q4 reported figures, RYOJ maintains a debt-to-equity ratio of 4.12, which, when viewed alongside an interest coverage ratio of 36.69, suggests that while the firm is currently meeting its obligations, its thin equity base leaves it highly vulnerable to any operational downturn.
The high leverage relative to the company's minimal shareholder equity indicates a precarious capital structure that may limit the firm's flexibility in a rising interest rate environment. Investors should monitor whether management intends to deleverage through retained earnings or if the current debt load is a permanent feature of the firm's financing strategy.
The P/E ratio is frequently misapplied to RYOJ because it fails to account for the significant disconnect between accounting net income and actual cash generation, as evidenced by the company's low OCF/NI ratio of 0.42 reported in the most recent quarterly filings.
Using P/E as the primary valuation metric obscures the reality that a large portion of the company's earnings may be tied up in working capital or non-cash items rather than available free cash flow. Analysts should instead focus on EV/FCF or adjusted cash-based metrics to better understand the true earning power of the firm's consulting and clinical operations.
Includes 30+ ratios · 2 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RYOJ stock.
rYojbaba Co., Ltd. Common Shares's current P/E ratio is 22.8x. This places it at the 50th percentile of its historical range.
rYojbaba Co., Ltd. Common Shares's current EV/EBITDA is 16.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
rYojbaba Co., Ltd. Common Shares's return on equity (ROE) is 68.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 61.9%.
Based on historical data, rYojbaba Co., Ltd. Common Shares is trading at a P/E of 22.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
rYojbaba Co., Ltd. Common Shares has 38.5% gross margin and 16.1% operating margin. Operating margin between 10-20% is typical for established companies.
rYojbaba Co., Ltd. Common Shares's Debt/EBITDA ratio is 4.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.